Search research articles
Contact Us
Filters
Showing results (31-40 of 58) with videos related to
Page
of 6
Sort By:
Endocrinology
|
July 2, 2020
Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma
Sreeja Sreekumar, Kevin M Levine, Matthew J Sikora, et al.
Cancer Letters
|
June 24, 2019
Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma
Lan Cao, Ahmed Basudan, Matthew J Sikora, et al.
American Journal of Clinical Pathology
|
May 10, 2018
Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?
Alessandra Landmann, Daniel J Farrugia, Li Zhu, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 4, 2026
Quantitative and qualitative patient-reported analysis of misdiagnosis and/or late diagnosis of metastatic lobular cancer
Morgan Elizabeth Cody, Hung-Ching Rick Chang, Julia Foldi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 7, 2019
Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy
Min Han, Arsalan Salamat, Li Zhu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 27, 2017
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors
Daniel J Farrugia, Alessandra Landmann, Li Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
Breast Cancer Research : BCR
|
April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Samuel A Jacobs, Ying Wang, Jame Abraham, et al.
NPJ Breast Cancer
|
July 20, 2024
International survey on invasive lobular breast cancer identifies priority research questions
Steffi Oesterreich, Leigh Pate, Adrian V Lee, et al.
NPJ Breast Cancer
|
March 21, 2024
Reporting on invasive lobular breast cancer in clinical trials: a systematic review
Karen Van Baelen, Josephine Van Cauwenberge, Marion Maetens, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 58) with videos related to
Sort By:
Page
of 6
Endocrinology
|
July 2, 2020
Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma
Sreeja Sreekumar, Kevin M Levine, Matthew J Sikora, et al.
Cancer Letters
|
June 24, 2019
Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma
Lan Cao, Ahmed Basudan, Matthew J Sikora, et al.
American Journal of Clinical Pathology
|
May 10, 2018
Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?
Alessandra Landmann, Daniel J Farrugia, Li Zhu, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 4, 2026
Quantitative and qualitative patient-reported analysis of misdiagnosis and/or late diagnosis of metastatic lobular cancer
Morgan Elizabeth Cody, Hung-Ching Rick Chang, Julia Foldi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 7, 2019
Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy
Min Han, Arsalan Salamat, Li Zhu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 27, 2017
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors
Daniel J Farrugia, Alessandra Landmann, Li Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
Jame Abraham, Albert J Montero, Rachel C Jankowitz, et al.
Breast Cancer Research : BCR
|
April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Samuel A Jacobs, Ying Wang, Jame Abraham, et al.
NPJ Breast Cancer
|
July 20, 2024
International survey on invasive lobular breast cancer identifies priority research questions
Steffi Oesterreich, Leigh Pate, Adrian V Lee, et al.
NPJ Breast Cancer
|
March 21, 2024
Reporting on invasive lobular breast cancer in clinical trials: a systematic review
Karen Van Baelen, Josephine Van Cauwenberge, Marion Maetens, et al.
Page
of 6